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Panic disorder (PD) has a lifetime prevalence of 2-4% and heritability estimates of 
40%. The contributory genetic variants remain largely unknown, with few and 
inconsistent loci having been reported. The present report describes the largest 
genome-wide association study (GWAS) of PD to date comprising genome-wide 
genotype data of 2 248 clinically well-characterized PD patients and 7 992 ethnically 
matched controls. The samples originated from four European countries (Denmark, 
Estonia, Germany, and Sweden). Standard GWAS quality control procedures were 
conducted on each individual dataset, and imputation was performed using the 1 000 
Genomes Project reference panel. A meta-analysis was then performed using the 
Ricopili pipeline. No genome-wide significant locus was identified. Leave-one-out 
analyses generated highly significant polygenic risk scores (explained variance of up 
to 2.6%). Linkage Disequilibrium (LD) Score regression analysis of the GWAS data 
showed that the estimated heritability for PD was 28.0-34.2%. After correction for 
multiple testing, a significant genetic correlation was found between PD and major 
depressive disorder, depressive symptoms, and neuroticism. A total of 255 single 
nucleotide polymorphisms (SNPs) with p<1x10-4 were followed up in an independent 
sample of 2 408 PD patients and 228 470 controls from Denmark, Iceland and the 
Netherlands. In the combined analysis, SNP rs144783209 showed the strongest 
association with PD (pcomb=3.10x10-7). Sign tests revealed a significant enrichment of 
SNPs with a discovery p value of <0.0001 in the combined follow up cohort (p=0.048). 
The present integrative analysis represents a major step towards the elucidation of the 




Panic disorder (PD) is one of the most severe anxiety disorders with a lifetime 
prevalence of around 2-4% and a lifetime morbid risk of 6% 1. PD is characterized by 
sudden and repeated attacks of fear that last for several minutes or longer. These are 
called panic attacks accompanied by a range of additional physiological or cognitive 
symptoms. Pathological worry about panic attacks, and the effort spent trying to avoid 
attacks, cause typically significant problems in various areas of the person’s life, 
including the development of agoraphobia and long-term disability 2. Family and twin 
studies indicate that the majority of cases with PD have a complex genetic basis 3, and 
have generated heritability estimates for PD of around 40% 4. However, on the 
molecular level little is known about the genetic contribution to PD, with only few and 
inconsistent findings reported to date. 
A genome-wide association study (GWAS) and follow up investigation by Erhardt et al. 
found evidence for an association between PD and two single-nucleotide 
polymorphisms (SNPs) in the gene TMEM132D on chromosome 12q24 5, 6. A GWAS 
by Otowa et al.7 identified several suggestive PD loci that failed to reach genome-wide 
significance 7. A recent GWAS meta-analysis of anxiety phenotypes - including PD - 
and quantitative phenotypic factor scores identified two genome-wide significant loci. 
These comprised an SNP in an uncharacterized non-coding RNA locus on 
chromosome 3q12, and an SNP within the gene CAMKMT on chromosome 2p21 8. 
While both SNPs are implicated in a shared anxiety disorder susceptibility, no study to 
date has investigated their contribution to specific clinical diagnoses, e.g., PD. 
The aim of the present study was to improve the characterization of PD on the 
molecular genetic level through the performance of a GWAS case-control meta-
analysis of data from more than 10 000 individuals. 
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In addition to the identification of single marker associations, analyses were performed 
to determine: 1) the degree of heritability attributable to common genetic variation; and 
2) genetic relationships between PD and anxiety-related phenotypes, other psychiatric 
disorders, education phenotypes and personality traits.  
 
Materials and Methods 
Sample description 
The GWAS discovery meta-analysis comprised 2 248 PD patients and 7 992 controls 
of European ancestry. The study was approved by the respective local ethics 
committees, and all participants provided written informed consent prior to inclusion. 
Six GWAS case-control cohorts were investigated. These originated from four 
European countries: Denmark, Estonia, Sweden, and Germany. The latter comprised 
three distinct cohorts: Germany I, Germany II, and Germany III. Patients were recruited 
at the following sites: Aarhus (n=99: Denmark); Copenhagen (n=155: Denmark); Tartu 
(n=346: Estonia); Gothenburg (n=192: Sweden); Stockholm (n=423: Sweden); Munich 
(n=6: Germany I, n=251: Germany II); Würzburg (n=426: Germany I, n=290: Germany 
III); and Bonn (n=60: Germany I). All patients had a lifetime diagnosis of PD according 
to DSM-III-R, DSM-IV, or ICD-10 criteria. Detailed descriptions of the samples are 
provided in the Supplemental Note. 
Controls for the three German cohorts were drawn from: a) the population-based Heinz 
Nixdorf Recall (HNR) Study9 (n=1 882: Germany I); and b) a Munich-based community 
cohort10 (n=538: Germany II; n=856: Germany III). The controls for the German II and 
III cohorts were screened for the presence of anxiety and affective disorders using the 
Composite International Diagnostic Screener. Only individuals negative for the above 
mentioned co-morbid disorders were included as controls. 
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Swedish controls (n=2 617)11 had no lifetime diagnosis of schizophrenia, 
schizoaffective disorder or bipolar disorder. Controls from Denmark (n=1 034) and 
Estonia (n=1 065) had no lifetime history of PD or any other mental disorder. 
 
Genotyping 
Genomic DNA was prepared from whole blood using standard procedures. DNA 
samples of PD patients were genome-wide genotyped using the Infinium 
HumanCoreExome (patients from Denmark, Estonia, Sweden, and Germany I), 
317K/610Q (Germany II) and 660W-Quad (Germany III) BeadChips (Illumina, San 
Diego, CA, USA). Genotyping of the German II patients was conducted at the Max-
Planck-Institute of Psychiatry, Munich, Germany. For the remaining PD patients, 
genotyping was performed at the Department of Genomics, Life & Brain Center, 
University of Bonn, Germany.  
Controls from Germany I were genotyped using the Illumina OmniExpress BeadChip 
at the Department of Genomics, Life & Brain Center, University of Bonn, Germany. For 
the remaining controls, genome-wide genotype data were obtained from previous 
studies (for further details see Supplemental Note). Genotyping in these studies was 
performed using: OmniExpress (Denmark, Estonia, and Sweden); 317K/610Q 
(Germany II); and 550K (Germany III).  
To facilitate data comparability, patients and controls from a given country were 
genotyped on arrays with large sets of overlapping markers. The individual cohorts, 
number of individuals, and genotyping arrays used in the present PD GWAS are 





Quality control and Imputation 
All Quality control (QC) and imputation procedures are described in detail elsewhere 
12, 13. Briefly, the QC parameters used for the exclusion of individuals and SNPs were: 
SNP missingness >0.05 (prior to the removal of individual subjects); SNP missingness 
per individual >0.02; autosomal heterozygosity deviation (|Fhet| >0.2); SNP 
missingness >0.02; difference in SNP missingness between patients and controls 
>0.02; and deviation of an SNP from Hardy-Weinberg equilibrium (p<10−10 in patients, 
p<10−6 in controls). 
Imputation of genotype data in each of the six individual case-control cohorts was 
carried out using IMPUTE2/SHAPEIT (pre-phasing/imputation stepwise approach; 
default parameters and a chunk size of 3 megabases (Mb))14, 15; and the 1 000 
Genomes Project reference panel (release “v3.macGT1”)16.  
Across all six case-control cohorts, relatedness testing and population structure 
analysis was conducted using a subset of 47 513 SNPs. These SNPs fulfilled stringent 
QC criteria (imputation INFO score >0.8; SNP missingness <0.01; minor allele 
frequency (MAF) >0.05), and had been subjected to linkage disequilibrium (LD) 
pruning (r2 >0.02). In cryptically related individuals, one member of each pair ( -hat 
>0.2) was removed at random, with patients being retained in preference to controls. 
Principal components (PCs) were estimated from the genotype data, and phenotype 
association was tested using logistic regression. Impact of PCs on the genome-wide 
test statistics was assessed using λ. 
The QC led to the exclusion of 333 individuals. Reasons for exclusion comprised: (i) 
insufficient data quality (low call rate): n=54; (ii) discrepancy between documented and 
genotyped sex: n=122; (iii) high heterozygosity rate deviation: n=6; (iv) subject 
relatedness (within and between samples): n=78; or (v) population outlier status: n=80. 
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After stringent QC, the final meta-analysis included data from 2 147 PD patients and 
7 760 controls (Supplementary Table 1).  
 
Association Analysis 
Meta-analysis of the six case-control GWAS cohorts was performed using the Ricopili 
pipeline (https://sites.google.com/a/broadinstitute.org/ricopili/). Single marker 
associations were tested using PCs 1-7, 11, 16, and 18 as covariates, and an additive 
logistic regression model, as implemented in PLINK 17. Genome-wide significance was 
set at a p-value threshold of 5x10-8. Meta-analysis was performed using METAL18, and 
by combining genetic effects (odds ratios, ORs) with inverse standard error (SE) 
weights.  
 
Polygenic risk score analysis 
The impact of polygenic risk on PD in the six individual GWAS cohorts was determined 
by calculating leave-one-out polygenic risk scores (PRS) for each subject of a given 
cohort, as based on the genetic association data of the five remaining GWAS datasets. 
PRS calculation is described in detail elsewhere13, 19. Briefly, to obtain a highly 
informative set of SNPs with minimal statistical noise, genetic variants with an MAF of 
<0.05 or an imputation INFO score of <0.9, as well as all insertions or deletions, were 
excluded. All remaining SNPs were then clumped, whereby markers within 500 
kilobases (kb) of, and in high LD (r2 ≥0.1) with, another more significant marker were 
discarded. From the major histocompatibility complex region on chromosome 6, only 
the variant with the most significant PD association was retained. PRS were calculated 
using 10 p-value association thresholds (5x10-8, 1x10-6, 1x10-4, 0.001, 0.01, 0.05, 0.1, 
0.2, 0.5, and 1.0). PRS computation also comprised multiplication of the natural 
logarithm of the OR of each variant by the imputation probability for the risk allele. The 
9 
resulting values were then totaled in order to generate PD PRS for each subject at 
each of the 10 p-value thresholds. 
Association between PRS and PD case-control status was analyzed using standard 
logistic regression. All PCs used in the association analysis (i.e., PCs 1-7, 11, 16 and 
18) were used as covariates. To calculate the proportion of variance explained 
(Nagelkerke’s R2) in PD case-control status for each p-value threshold, scores 
generated from a full model (covariates and PRS) and a reduced model (covariates 
only) were compared. 
 
LD Score regression 
SNP-based heritability for PD was calculated using the LD Score regression method 
20. To take into account different prevalence estimates, we determined the SNP-based 
heritability for a PD lifetime prevalence of 2% and 4%. 
In addition, LD Hub analyses (http://ldsc.broadinstitute.org/)21 were performed in order 
to investigate a possible genetic overlap between PD and other diseases/phenotypes. 
LD Hub is a centralized database of GWAS summary statistics for a range of diseases 
and traits that automates the estimation of genetic correlations 21. In the present study, 
a focused analysis was performed of a total of 16 psychiatric, personality, and 
education phenotypes available in LD Hub. In addition, the LD Score regression 
method and summary statistics of previous GWAS8, 22, 23 were used to calculate the 
possible genetic correlation between PD and anxiety phenotypes; posttraumatic stress 
disorder (PTSD); and obsessive-compulsive disorder. The resulting p-values were 
Bonferroni corrected for multiple testing, taking into account the number of investigated 
phenotypes (n=19). No overlap was present between cases from the present PD 
GWAS meta-analysis and the other GWAS. The LD Score method is robust with 




Calculation of gene-based tests, and the performance of gene-set enrichment and 
tissue enrichment analyses, was performed using the MAGMA software24, as 
implemented in the FUMA platform25. A detailed description of the biostatistical 
analyses implemented in FUMA is provided elsewhere 25.  
Briefly, the summary statistics of the present PD GWAS were used as input. Due to 
the absence of genome-wide significant SNPs, an MAF of ≥0.01 and an association p-
value threshold of 1x10-5 were used to define lead SNPs. An r2 of ≥0.6 and a genomic 
window of ± 250 kb were used to determine LD with independent lead SNPs. 
 
Follow up analysis 
A total of 255 PD SNPs with a p value of <1x10-4, an MAF >0.01 and an imputation 
INFO score of >0.5 were followed up in an independent sample comprising 2 408 PD 
patients and 228 470 controls. The respective subjects were drawn from three 
independent European datasets: iPSYCH (Denmark, n=905 cases, n=3 620 controls); 
deCODE (Iceland, n=547 cases, n=220 285 controls); and NESDA/NTR (the 
Netherlands, n=956 cases, n=4 565 controls). The Supplemental Note provides 
detailed information on each follow up GWAS. As in the discovery step, a meta-
analysis was performed using inverse SE weighted OR combination. To analyze the 








Single marker association analysis 
A total of 8 757 275 single markers passed QC and were included in the analyses. 
Single marker analysis revealed no genome-wide significant finding for PD (Figure 1). 
Seven independent chromosomal regions showed a suggestive association p-value of 
<1x10-6. The PD variant with the lowest p-value was a small deletion in an intergenic 
region on chromosome 14 (p=1.01x10-7, OR=1.64, MAF in cases=0.07, imputation 
INFO score =0.59). PD associated single markers with p<1x10-5 are listed in 
Supplementary Table 2.  
 
Polygenic risk score analysis 
Leave-one-out PRS significantly predicted case-control status in all investigated 
cohorts (Figure 2). The analyses demonstrated highly significant PRS, with maximum 
explained variance ranging from 0.8% (Sweden) to 2.6% (Germany II). 
 
LD Score regression analysis 
Estimated SNP-based heritability for PD ranged from 28.0% (standard deviation (SD) 
5.7%, lifetime prevalence of 2%) to 34.2% (SD 6.9%, lifetime prevalence of 4%).  
In the genetic correlation analysis, an experiment-wide significant genetic correlation 
with PD was found for major depressive disorder (MDD) (rg=0.431; SE=0.134; 
pcorr=0.025); depressive symptoms (rg=0.322; SE=0.093; pcorr=0.010); and neuroticism 
(rg=0.316; SE=0.082; pcorr=0.002; Figure 3). 
In addition, nominally significant genetic correlations were found for anxiety disorders; 
PTSD; the Psychiatric Genomics Consortium (PGC) cross-disorder analysis 
phenotype; schizophrenia; and years of schooling (Figure 3).  
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MAGMA: Gene-based analysis 
MAGMA gene-based analyses were performed for a total of 18 335 genes. No gene 
showed significant association with PD after correction for multiple testing (P>0.05/18 
335 or P>2.73x10-6). Genes with p<0.001 are listed in Supplementary Table 3.  
 
MAGMA: Gene-set and tissue expression enrichment analyses 
MAGMA gene-set analysis revealed a total of 521 nominally significantly enriched 
gene-sets or pathways, which showed partial overlap in terms of underlying genes 
(Supplementary Table 4). However, none of these gene-sets showed significant 
enrichment in PD after Bonferroni correction for multiple testing (P>0.05/10 891 or 
P>4.59x10-6). 
MAGMA tissue expression profile analysis revealed that genes identified in the present 
PD GWAS were enriched for expression in various brain tissues (Figure 4). The 
strongest enrichment was observed for genes expressed in the cortex, followed by the 
amygdala. None of the investigated tissues showed significant enrichment after 
correction for multiple testing (data not shown). 
 
Follow up analysis 
The combined analysis (including follow up results) revealed no genome-wide 
significant PD association at p<5x10-8. The lowest p-value in relation to PD was found 
for SNP rs144783209 (pcomb=3.10x10-7). This variant is located in intron 1 of the gene 
SMAD1. All SNPs from the combined analysis with an association to PD at p<1x10-5 
are shown in Table 1. 
Sign tests for SNPs with a discovery significance of p<0.0001 (n=243) revealed a 
significant enrichment of nominally significant associated SNPs with the same effect 
direction (n=135) in the combined follow up cohort (p=0.048). 
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Discussion 
To our knowledge, the present collaborative study represents the largest GWAS meta-
analysis of PD to date. The findings provide new insights into the molecular genetic 
architecture of PD. 
Leave-one-out PRS significantly predicted case-control status in all investigated sub-
cohorts. This demonstrates the consistency of PD association between sub-cohorts on 
the polygenic level, and suggests that uniform diagnostic criteria were applied. 
Although the phenotypic variance explained by the use of the current sample size was 
relatively small (ranging from R2 =0.8% to R2 =2.6%), it is comparable to that found for 
other complex genetic phenotypes at comparable sample sizes, e.g., schizophrenia 12, 
19.  
The present LD Score regression analysis was based on genome-wide genotype data 
from  around 10 000 individuals, and provides the first SNP-based heritability estimate 
for PD. Estimated heritability ranged between 28% and 34%, suggesting that common 
genetic variation explains ≥70% of the total heritability estimated by twin studies. This 
implies that a large proportion of PD susceptibility is influenced by common genetic 
variants with small effect sizes. 
The present analyses identified a significant positive genetic correlation between PD 
and MDD, depressive symptoms, and neuroticism. The genetic correlation between 
PD and MDD/depressive symptoms is consistent with their frequently observed 
comorbidity in clinical practice 26. In addition, the results are consistent with previous 
findings of overlapping genetic risk profiles for depression and anxiety scores27. 
Information concerning the presence or absence of a lifetime history of comorbid MDD 
was available for 1 153 of the present PD patients. Of these, 372 individuals had a 
lifetime history of MDD. Therefore, the possibility that comorbidity inflated the 
calculated genetic correlation between PD and MDD cannot be excluded. 
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The most significant genetic correlation with PD was found for neuroticism – a trait 
measure that is highly correlated with all internalizing mental disorders. This is in line 
with previous findings of a possible correlation between PD and neuroticism 28. Studies 
of neuroticism have also identified positive correlations with other anxiety disorders 
and MDD29-31. Previous authors have therefore hypothesized that the trait dimension 
“neuroticism” may represent an intermediate phenotype 32, which is more directly 
influenced by the underlying risk genes than the psychiatric phenotype per se. This 
may suggest that rather than being psychiatric disease-states, anxiety disorders and 
MDD may represent the (quantitative) extremes of dimensions that underlie normal 
personality. In terms of PD, a plausible hypothesis is that individuals with high scores 
for neuroticism are more likely to experience feelings such as anxiety and fear, which 
might lead to a higher sensitivity to interoceptive signals and symptom perception, and 
thus to the manifestation of, or vulnerability to, panic attacks. 
The present analyses also identified a nominally significant positive genetic correlation 
between PD and anxiety disorders (including PD); PTSD; the PGC cross-disorder 
phenotype; schizophrenia; and negative correlation with years of schooling. Future 
studies are warranted to replicate these findings in genetic data from larger cohorts. 
MAGMA gene-based-, gene-set-, and tissue expression profile analyses revealed no 
significantly associated genes or enriched gene-sets/tissues after correction for 
multiple testing. Interestingly, these results might suggest that genes implicated in the 
present PD GWAS are enriched for expression in various brain tissues, thus providing 
further evidence that the biological origin of PD lies in the brain. Notably, the strongest 
enrichment was observed for genes expressed in the cortex and the amygdala, i.e., 
brain regions that play a central role in the neural network of anxiety and fear 33, 34. 
Interestingly, alterations within these brain regions have been reported in 
neuroimaging studies of patients with PD 33, 35. 
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As expected for both a GWAS of a complex psychiatric disorder and the size of the 
respective meta-analysis, no genome-wide significant association was found for PD in 
the present sample. However, in the combined analysis of all available GWAS data, 
six SNPs showed a p-value of <1x10-5 (Table 1). Future studies are warranted to 
replicate these findings in genetic data from larger cohorts. This could be achieved by 
combining the GWAS data of individual studies within large international consortia, 
e.g., the PGC 36. 
The present study had several limitations. First, although the total sample size 
exceeded those used in previous genetic studies of PD, it remained relatively 
underpowered in terms of the detection of common variants with small effects for the 
complex PD phenotype36. Based on the significant results obtained in the sign test, the 
present authors anticipate that genetic associations with PD will become increasingly 
robust with increasing sample sizes, and that a proportion of these currently suggestive 
findings will achieve genome-wide significance in future studies. 
Second, the results were obtained using data from individuals of European ancestry, 
and may not be generalizable to individuals from other cultural or genetic 
backgrounds8. 
Third, anxiety disorders are heterogeneous clinical phenotypes, and the extent to 
which clinical nosology reflects the underlying etiological mechanisms remains 
unclear. In addition, to varying extents, genetic and environmental risk factors show 
non-specific effects across the various anxiety disorder categories8. Future cross-
disorder studies, as well larger meta-analyses of PD and other individual anxiety 






To our knowledge, the present study represents the largest GWAS of PD to date. 
Although no genome-wide significant locus was identified, the analyses generated the 
first SNP-based heritability estimate for PD and revealed a significant genetic overlap 
with depression and neuroticism. The results suggest that rather than being a discrete 
entity, PD has an etiological overlap with personality traits and other psychiatric 
disorders. Further investigation of shared and non-shared clinical and genetic 
characteristics is therefore warranted. This will facilitate the development of new and 
personalized PD treatment approaches. 
 
Acknowledgements 
The authors are grateful to all patients and control subjects for their participation. We 
thank Kristina Annerbrink (Gothenburg), Marie Olsson (Gothenburg) and Monica 
Hellberg (Stockholm) for their support. The study was supported by the German 
Research Foundation (DFG; grant SCHU1596/4-1 to J. Schumacher). Controls for the 
Germany I sample were drawn from the Heinz Nixdorf Recall Study (HNR) cohort, 
which was established with the support of the Heinz Nixdorf Foundation. A. Metspalu 
was supported by EstRC grant IUT20-60 and by the European Union through the 
European Regional Development Fund (Project No. 2014-2020.4.01.15-0012), Centre 
of Excellence “GenTransMed”. 
This work was conducted within the framework of the German multicenter trial 
“Mechanisms of Action in CBT (MAC)”. The MAC study was funded by the German 
Federal Ministry of Education and Research (BMBF; project no. 01GV0615), as part of 
the BMBF Psychotherapy Research Funding Initiative. 
17 
Principal investigators (PI) with respective areas of responsibility in the MAC study are: 
V. Arolt (Münster: Overall MAC Program Coordination); H.U. Wittchen (Dresden: PI for 
the Randomized Clinical Trial (RCT) and Manual Development); A. Hamm (Greifswald: 
PI for Psychophysiology); A.L. Gerlach (Münster: PI for Psychophysiology and Panic 
subtypes); A. Ströhle (Berlin: PI for Experimental Pharmacology); T. Kircher (Marburg: 
PI for functional neuroimaging); and J. Deckert (Würzburg: PI for Genetics). Additional 
site directors for the RCT component of the program are G.W. Alpers (Würzburg); T. 
Fydrich and L. Fehm (Berlin-Adlershof); and T. Lang (Bremen). 
Acknowledgements and staff members according to site 
Greifswald (coordinating site for Psychophysiology): Christiane Melzig, Jan Richter, 
Susan Richter, Matthias von Rad; Berlin-Charité (coordinating Center for Experimental 
Pharmacology): Harald Bruhn, Anja Siegmund, Meline Stoy, André Wittmann; Berlin-
Adlershof: Irene Schulz; Münster (Overall MAC Program Coordination, Genetics and 
Functional Neuroimaging): Andreas Behnken, Katharina Domschke, Adrianna Ewert, 
Carsten Konrad, Bettina Pfleiderer, Christina Uhlmann, Peter Zwanzger; Münster 
(coordinating site for psychophysiology and subtyping): Judith Eidecker, Swantje 
Koller, Fred Rist, Anna Vossbeck-Elsebusch; Marburg/Aachen (coordinating center for 
functional neuroimaging): Barbara Drüke, Sonja Eskens, Thomas Forkmann, Siegfried 
Gauggel, Susan Gruber, Andreas Jansen, Thilo Kellermann, Isabelle Reinhardt, Nina 
Vercamer-Fabri; Dresden (coordinating site for data collection, analysis, and the RCT): 
Franziska Einsle, Christine Froehlich, Andrew T. Gloster, Christina Hauke, Simone 
Heinze, Michael Hoefler, Ulrike Lueken, Peter Neudeck, Stephanie Preiß, Dorte 
Westphal; Würzburg Psychiatry Department (coordinating center for genetics): 
Andreas Reif, Caro Gagel; Würzburg Psychology Department: Julia Duerner, Hedwig 
Eisenbarth, Antje B. M. Gerdes, Harald Krebs, Paul Pauli, Silvia Schad, Nina 
18 
Steinhäuser; Bremen: Veronika Bamann, Sylvia Helbig-Lang, Anne Kordt, Pia Ley, 
Franz Petermann, Eva-Maria Schroeder. Additional support was provided by the 
coordinating center for clinical studies in Dresden (KKS Dresden): Xina Graehlert and 
Marko Käppler. 
 
This work is also part of the German multicenter trial “Mechanisms of CBT-treatment 
effects in patients with panic disorder and panic disorder with agoraphobia: The role of 
interoceptive exposure and fear augmentation (MCBT-PDAS)”. The MCBT-PDAS 
study is funded by the German Federal Ministry of Education and Research (BMBF, 
01GV0614), as part of the larger BMBF Psychotherapy Research Funding Initiative 
“Improving the Treatment of Panic Disorder”.  
The PIs of the MCBT-PDAS study are: Alfons Hamm (Greifswald: PI 
Psychophysiology); Thomas Lang (Bremen: Study Director for the RCT and Manual 
Development); Alexander L. Gerlach (Münster: PI Panic subtypes); Georg W. Alpers 
(Mannheim: PI Ambulatory assessment); Christiane Pané-Farré (Greifswald: PI 
Psychophysiology and Panic Disorder); Tilo Kircher (Marburg: PI for functional 
neuroimaging), and Jürgen Deckert (Würzburg: PI for Genetics). Additional site 
directors for the RCT component of the program are Winfried Rief (Marburg), and Paul 
Pauli (Würzburg). 
Centers of the Research Network: Volker Arolt (Münster: Overall Network 
Coordination); Hans-Ulrich Wittchen (Dresden); Andreas Ströhle (Berlin). 
Data Access and Responsibility: All PIs take responsibility for the integrity of the 
respective study data and their components. All authors and co-authors had full access 
to all study data. Data analysis and manuscript preparation were completed by the 
19 
authors and co-authors of this article, who take responsibility for its accuracy and 
content.  
Acknowledgements and staff members by site: Bremen (coordinating center for the 
multicenter trial): Veronika Bamann, Sandra Cammin, Sarah Czilwik, Kira Geisler, 
Sylvia Helbig-Lang, Kirsten Helmes, Anne Kordt, Tanja Leonhard, Mila Plett-
Perelshteyn, Christian Soltau, Juliane Sülz, Maxie von Auer; Greifswald (coordinating 
site for psychophysiology): Anett Hoffmann, Jan Richter; Mannheim (coordinating 
center for ambulatory assessment): Christoph Biwer, Elisabeth Borgmann, Antje 
Gerdes, Otto Martin, Kristina Steinbach, Bettina Stemmler, Andrew White; Marburg 
(coordinating center for functional neuroimaging): Tobias Fehlinger, Andreas Jansen, 
Nikita Jegan, Carsten Konrad, Marion Mickeler, Silke Rusch, Katrin Schlötterer, 
Benjamin Straube, Mareike Stumpenhorst, Katrin Wambach, Yunbo Yang; Münster 
(coordinating site for panic subtypes): Susanne Kettler, Anna Vossbeck-Elsebusch; 
Würzburg Psychiatry Department (coordinating center for genetics): Carola Gagel, 
Andreas Reif, Heike Weber; Würzburg Psychology Department: Almut Friedl-Huber, 
Harald Krebs, Caroline Ott, Nina Steinhäuser. Additional support was provided by the 
coordinating center for clinical studies in Dresden (KKS Dresden): Marko Käppler. 
The study was registered with the NCT01323556. 
 
Funding for the Netherland Twin Register and Netherlands Study of Depression and 
Anxiety (NESDA) was obtained from the Netherlands Organization for Scientific 
Research (NWO) and MagW/ZonMW grants Middelgroot-911-09-032, Spinozapremie 
56-464-14192, Geestkracht program of the Netherlands Organization for Health 
Research and Development (ZonMW 10-000-1002), Center for Medical Systems 
Biology (CSMB, NOW Genomics), Genetic influences on stability and change in 
psychopathology from childhood to young adulthood (ZonMW 912-10-020), 
20 
NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research 
Infrastructure (BBMRI–NL, 184.021.007), VU University’s Institute for Health and Care 
Research (EMGO+) and Neuroscience Campus Amsterdam (NCA); the European 
Science Council (ERC Advanced, 230374). The genotyping and analyses were funded 
in part by the Genetic Association Information Network (GAIN) of the Foundation for 
the National Institutes of Health, Rutgers University Cell and DNA Repository (NIMH 
U24 MH068457-06); the Avera Institute for Human Genetics, Sioux Falls, South 
Dakota (USA); and the National Institutes of Health (NIH R01 HD042157-
01A1,MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). 
The iPSYCH project is funded by the Lundbeck Foundation (grant numbers R102-
A9118 and R155-2014-1724) and the universities and university hospitals of Aarhus 
and Copenhagen. The Danish National Biobank resource was supported by the Novo 
Nordisk Foundation. Data handling and analysis on the GenomeDK HPC facility was 
supported by NIMH (1U01MH109514-01 to Michael O’Donovan and Anders D. 
Børglum). High-performance computer capacity for handling and statistical analysis of 
iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics 
and Personalized Medicine, Aarhus University and Central Region Denmark, and 
Centre for Integrative Sequencing, iSEQ, Aarhus University (grant to Anders D. 
Børglum). 
 
Conflict of Interest 
T.E.T., S.S., H.S. and K.S. are employed by deCODE Genetics/Amgen. T.W. has 
acted as advisor and lecturer to H. Lundbeck A/S. The other authors have no conflicts 
of interest to declare. 
 
Supplementary information is available at the Molecular Psychiatry website. 
21 
References 
1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-
month and lifetime prevalence and lifetime morbid risk of anxiety and mood 
disorders in the United States. Int J Methods Psychiatr Res 2012; 21(3): 169-
184. 
 
2. Hendriks SM, Spijker J, Licht CM, Beekman AT, Hardeveld F, de Graaf R et al. 
Disability in anxiety disorders. J Affect Disord 2014; 166: 227-233. 
 
3. Schumacher J, Deckert J. Serotonin transporter polymorphisms and panic 
disorder. Genome Med 2010; 2(6): 40. 
 
4. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic 
epidemiology of anxiety disorders. Am J Psychiatry 2001; 158(10): 1568-1578. 
 
5. Erhardt A, Akula N, Schumacher J, Czamara D, Karbalai N, Muller-Myhsok B et 
al. Replication and meta-analysis of TMEM132D gene variants in panic 
disorder. Transl Psychiatry 2012; 2: e156. 
 
6. Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S et al. 
TMEM132D, a new candidate for anxiety phenotypes: evidence from human 
and mouse studies. Mol Psychiatry 2011; 16(6): 647-663. 
 
7. Otowa T, Kawamura Y, Nishida N, Sugaya N, Koike A, Yoshida E et al. Meta-
analysis of genome-wide association studies for panic disorder in the Japanese 
population. Transl Psychiatry 2012; 2: e186. 
22 
 
8. Otowa T, Hek K, Lee M, Byrne EM, Mirza SS, Nivard MG et al. Meta-analysis 
of genome-wide association studies of anxiety disorders. Mol Psychiatry 2016; 
21(10): 1391-1399. 
 
9. Schmermund A, Mohlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H 
et al. Assessment of clinically silent atherosclerotic disease and established and 
novel risk factors for predicting myocardial infarction and cardiac death in 
healthy middle-aged subjects: rationale and design of the Heinz Nixdorf 
RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am 
Heart J 2002; 144(2): 212-218. 
 
10. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ et al. 
Genome-wide association study of recurrent major depressive disorder in two 
European case-control cohorts. Mol Psychiatry 2010; 15(6): 589-601. 
 
11. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S et al. 
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. 
Nat Genet 2013; 45(10): 1150-1159. 
 
12. Schizophrenia Working Group of the Psychiatric Genomics Consortium. 
Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 
511(7510): 421-427. 
 
13. Witt SH, Streit F, Jungkunz M, Frank J, Awasthi S, Reinbold CS et al. Genome-
wide association study of borderline personality disorder reveals genetic overlap 
23 
with bipolar disorder, major depression and schizophrenia. Transl Psychiatry 
2017; 7(6): e1155. 
 
14. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for 
thousands of genomes. Nat Methods 2011; 9(2): 179-181. 
 
15. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of 
genomes. G3 (Bethesda) 2011; 1(6): 457-470. 
 
16. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks 
LD, Durbin RM et al. A map of human genome variation from population-scale 
sequencing. Nature 2010; 467(7319): 1061-1073. 
 
17. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. 
PLINK: a tool set for whole-genome association and population-based linkage 
analyses. Am J Hum Genet 2007; 81(3): 559-575. 
 
18. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics 2010; 26(17): 2190-2191. 
 
19. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, 
Visscher PM, O'Donovan MC et al. Common polygenic variation contributes to 
risk of schizophrenia and bipolar disorder. Nature 2009; 460(7256): 748-752. 
 
24 
20. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR et al. An 
atlas of genetic correlations across human diseases and traits. Nat Genet 2015; 
47(11): 1236-1241. 
 
21. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC et 
al. LD Hub: a centralized database and web interface to perform LD score 
regression that maximizes the potential of summary level GWAS data for SNP 
heritability and genetic correlation analysis. Bioinformatics 2017; 33(2): 272-
279. 
 
22. Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-
Koch AE et al. Largest GWAS of PTSD (N=20 070) yields genetic overlap with 
schizophrenia and sex differences in heritability. Mol Psychiatry 2018; 23(3): 
666-673. 
 
23. International Obsessive Compulsive Disorder Foundation Genetics 
Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association 
Studies (OCGAS). Revealing the complex genetic architecture of obsessive-
compulsive disorder using meta-analysis. Mol Psychiatry 2018; 23(5): 1181-
1188. 
 
24. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-
set analysis of GWAS data. PLoS Comput Biol 2015; 11(4): e1004219. 
 
25 
25. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping 
and annotation of genetic associations with FUMA. Nat Commun 2017; 8(1): 
1826. 
 
26. Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S et al. Clinical 
characteristics and treatment outcomes of patients with major depressive 
disorder and comorbid anxiety disorders - results from a European multicenter 
study. J Psychiatr Res 2017; 91: 1-13. 
 
27. Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS et al. 
Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol 
Psychiatry 2011; 16(7): 773-783. 
 
28. Vohma U, Aluoja A, Vasar V, Shlik J, Maron E. Evaluation of personality traits 
in panic disorder using Swedish universities Scales of Personality. J Anxiety 
Disord 2010; 24(1): 141-146. 
 
29. Bienvenu OJ, Hettema JM, Neale MC, Prescott CA, Kendler KS. Low 
extraversion and high neuroticism as indices of genetic and environmental risk 
for social phobia, agoraphobia, and animal phobia. Am J Psychiatry 2007; 
164(11): 1714-1721. 
 
30. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major 
depression: a Swedish longitudinal, population-based twin study. Arch Gen 
Psychiatry 2006; 63(10): 1113-1120. 
 
26 
31. Navrady LB, Adams MJ, Chan SWY, Major Depressive Disorder Working Group 
of the Psychiatric Genomics Consortium, Ritchie SJ, McIntosh AM. Genetic risk 
of major depressive disorder: the moderating and mediating effects of 
neuroticism and psychological resilience on clinical and self-reported 
depression. Psychol Med 2018; 48(11): 1890-1899. 
 
32. Goldstein BL, Klein DN. A review of selected candidate endophenotypes for 
depression. Clin Psychol Rev 2014; 34(5): 417-427. 
 
33. Dresler T, Guhn A, Tupak SV, Ehlis AC, Herrmann MJ, Fallgatter AJ et al. 
Revise the revised? New dimensions of the neuroanatomical hypothesis of 
panic disorder. J Neural Transm (Vienna) 2013; 120(1): 3-29. 
 
34. Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN et al. 
The structural and functional connectivity of the amygdala: from normal emotion 
to pathological anxiety. Behav Brain Res 2011; 223(2): 403-410. 
 
35. Pfleiderer B, Zinkirciran S, Arolt V, Heindel W, Deckert J, Domschke K. fMRI 
amygdala activation during a spontaneous panic attack in a patient with panic 
disorder. World J Biol Psychiatry 2007; 8(4): 269-272. 
 
36. Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Borglum AD, Breen G et al. 




37. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) 



























Figure 1: Manhattan plot 
Manhattan plot for the discovery genome-wide association analysis of data from 2 147 
panic disorder patients and 7 760 controls. -log10 p-values are plotted for all variants 
across chromosomes 1-22. Green diamonds indicate loci with a lead variant genome 
wide association study p-value of <5x10-7. The red line indicates the threshold for 
genome-wide significance (p-value of 5x10-8). 
 
Figure 2: Leave-one-out polygenic risk score (PRS) analysis 
The results of the leave-one-out PRS analysis for the six genome-wide association 
study (GWAS) cohorts are depicted. Leave-one-out PRS were calculated for each 
subject of a given cohort using the genetic association data of the remaining five 
GWAS datasets and 10 p-value thresholds (denoted by the color of the respective bar). 
Statistical significance of the variance explained by the PRS (R squared) is depicted 
over each corresponding bar. 
 
Figure 3: Genetic correlations between panic disorder and other phenotypes 
Genetic correlations between panic disorder and 19 psychiatric, personality, and 
education phenotypes are shown. For each phenotype, the genetic correlation (dot) 
and the standard error (line) are shown. The significance level of the genetic correlation 
is indicated by the color of the respective dot (see legend). Abbreviations: Anxiety, 
anxiety disorders; PTSD, posttraumatic stress disorder; PGC, Psychiatric Genomics 





Figure 4: MAGMA tissue expression analysis 
Overview of the results of the MAGMA 24 tissue enrichment analysis, as implemented 
in FUMA 25, using GTEx data for 53 tissue types37. Nominal -log10 p-values are shown 
on the y-axis. None of the investigated tissues showed a significant enrichment after 




Table 1: List of variants with p<1x10-5 in the combined analysis 
Variants with a p-value <1x10-5 in the combined analysis are listed. Abbreviations: Chr, 
chromosome; bp, base pair (hg19); A1/A2, allele 1/2; P, p-value in the discovery 
GWAS; OR, odds ratio in the discovery GWAS; follow_up_dir, effect direction in the 
combined follow up sample; P_follow_up, p-value in the follow up sample; 
OR_follow_up, odds ratio in the follow up sample; P_comb, p-value in the combined 















Supplementary Table 1: Overview of the genotyping and quality control for the six 
discovery GWAS cohorts 
Supplementary Table 2: List of variants with p<1x10-5 in the discovery GWAS 
Supplementary Table 3: Genes with a nominal p<0.001 in the MAGMA gene-based 
analysis 







Variant Chr Position (bp) A1/A2 P OR follow_up_dir P_follow_up OR_follow_up P_comb OR_comb Nearby gene/s 
rs144783209 4 146403529 T/G 1.47E-06 1.70 + 0.0123 1.30 3.10E-07 1.47 SMAD1 
rs79919349 20 55282846 A/G 4.71E-07 2.26 + 0.1491 1.30 2.28E-06 1.77 - 
rs41280169 9 114982937 T/C 6.00E-07 1.66 + 0.0881 1.18 2.51E-06 1.40 SUSD1, PTBP3 
rs2554444 15 25257585 A/T 5.01E-05 0.79 + 0.0088 0.87 2.84E-06 0.83 SNRPN, SNURF 
rs112586150 15 25246958 A/G 3.10E-06 1.58 + 0.0720 1.20 4.43E-06 1.38 SNRPN, SNURF 
rs6914428 6 63230740 A/G 4.02E-05 0.81 + 0.0161 0.89 4.68E-06 0.85 - 
 
